viewAstraZeneca PLC

AstraZeneca receives US priority review for asthma candidate

A final decision is expected in the first quarter of 2022

AstraZeneca - AstraZeneca receives US priority review for asthma candidate

AstraZeneca PLC (LON:AZN) announced an asthma treatment developed with Amgen has been granted priority review in the US.

Tezepelumab reached all objectives in late-stage trials and showed better results than placebo.

READ: AstraZeneca is a key pick, but which other stocks are on this top bank's 'buy' list?

The US Food and Drug Administration (FDA) grants the review to candidates that have more advantages compared to approved medicines, for instance demonstrating safety or efficacy improvements, preventing serious conditions or increasing patient compliance.

The FTSE 100 group expects a decision during the first quarter of 2022.

The pharma company said despite recent advances in severe asthma, many patients may not qualify for or respond well to current medicines.

Patients with severe, uncontrolled asthma experience frequent episodes, significant limitations on lung function and lower quality of life.

"This decision brings us a step closer to delivering a much-needed, first-in-class medicine for asthma patients, many of whom remain uncontrolled and at risk of asthma attacks despite the availability of inhaled and biologic medicines,” said Mene Pangalos, executive vice president of BioPharmaceuticals R&D.

“Tezepelumab has demonstrated reductions in exacerbations irrespective of blood eosinophil counts, allergy status and fractional exhaled nitric oxide, and has the potential to transform treatment for a broad population of severe asthma patients."

Quick facts: AstraZeneca PLC


Price: 8233 GBX

Market Cap: £127.46 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


iClima Earth: When will the grid be green and how much storage will that...

iClima Earth's Gabriela Herculano talks to Proactive London about the debate on whether the US energy system (or that of any country) should be 100% renewable energy based.  As she explains, the problem is intermittency, 'as the sun does not shine and the wind does not blow all the...

1 hour, 11 minutes ago

2 min read